


# KNOW YOUR NETS!


Gastrointestinal and pancreatic neuroendocrine tumors, better known as GEP-NETs, are rare tumors formed from cells that have roles in both the endocrine and the nervous system.<sup>1</sup> NETs are now ranked as the second most prevalent GI malignancy (behind colon cancer); however, they usually remain undiagnosed for years.<sup>2</sup>

At least **112,000** people in the United States are living with GEP-NETs in the United States.<sup>3,4</sup>



Starting in the gastrointestinal tract, which includes the stomach, intestine, appendix, colon, or rectum.<sup>1</sup>

## THE NEED-TO-KNOW FACTS ABOUT GEP-NETS



patients with NET already have liver metastases at diagnosis.<sup>5</sup>



the median overall survival in patients with liver metastases.<sup>5</sup>




5 out of 100,000 people in the US diagnosed.<sup>2</sup>



Average time from initial onset of symptoms to proper diagnosis.<sup>2</sup>


Patient advocacy groups have adopted the zebra as the symbol of GEP-NETs as both are rare and no two are exactly alike.



## TYPES OF GEP-NETS

### GI-NETs

(gastrointestinal neuroendocrine tumors)



Diagnoses in U.S. per year **16,000**<sup>4,6</sup>



Overall 5 - year survival rate **89.2%**<sup>7</sup>

### pNETs

(pancreatic neuroendocrine tumors)



Diagnoses in U.S. per year **1,000**<sup>8</sup>



Overall 5 - year survival rate **42%**<sup>8</sup>

## SYMPTOMS



NET can remain undiagnosed for years due to vague abdominal symptoms that are often attributed to irritable bowel or Crohn's<sup>9</sup>

Symptoms can include:

- diarrhea
- hot red flushing of the face
- rapid heartbeat
- asthma-like wheezing attacks<sup>1</sup>

Additional symptoms:

- abdominal pain
- nausea
- vomiting<sup>1</sup>

## TREATMENT



### STRATEGIES

- Remove tumors
- Slow the disease progression
- Reduce symptoms



### EARLY DIAGNOSIS

If experiencing symptoms, speak to your doctor about possible risk factors. Advocate for yourself, doctors are less likely to look for rare diseases.



### TREATMENT

- Surgery
- Medical therapy

1. American Cancer Society. Detailed guide. Gastrointestinal carcinoid tumors. What is it? Available at: <http://www.cancer.org/cancer/gastrointestinalcarcinoidtumor/detailedguide/gastrointestinal-carcinoid-tumors-what-is-gastrointestinal-carcinoid>. Accessed October 31, 2014.  
 2. Modlin, IM, Moss, SF, Chung, DC, Jensen, RT, & Snyderwine E (2008). Priorities for improving the Management of Gastroenteropancreatic Neuroendocrine Tumors. *Journal of the National Cancer Institute*, 100, 1282-1289.  
 3. Öberg, K, Knigge, U, Kwelkboom, D, Perren, A. (2012). Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 23(Supplement 7), 124-130.  
 4. United States Census Bureau. Census Website. <http://www.census.gov/popest/>. Accessed December 10, 2014.  
 5. Steinmüller T, Kianmanesh R, Falconi M, et al. (2008) Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary. *Neuroendocrinology*, 87(47), 47-62.  
 6. Yao JC, Hassan M, Phan AT, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *Journal of Clinical Oncology*, 26(18), 3063-3072.  
 7. Panzuto, F. (2005). Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. *Endocrine Related Cancer*, 10(83-1092).  
 8. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Homer M-J (2007). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215.  
 9. Claxton, W, Poon, D (2010). Carcinoid & Neuroendocrine Tumor Society of Singapore (CNETS) Survey on Delay in Diagnosis of Neuroendocrine Tumors (Abstract). Presented at 35th Congress of the European Society for Medical Oncology.

Brought to you by Ipsen



NET00131